Header Logo

Connection

RAJKUMAR VENKATRAMANI to Female

Back to Details
This is a "connection" page, showing publications RAJKUMAR VENKATRAMANI has written about Female.
RAJKUMAR VENKATRAMANI
Connection Strength
1.358
Female
  1. Extremity rhabdomyosarcoma in children, adolescents and young adults: A report from Children's Oncology Group trials. Cancer. 2025 Jun 15; 131(12):e35929.
    View in: PubMed
    Score: 0.036
  2. Nonorbital, Nonparameningeal Head and Neck Rhabdomyosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2025 Jun; 72(6):e31673.
    View in: PubMed
    Score: 0.035
  3. Multicenter Retrospective Analysis of Pediatric Differentiated Thyroid Carcinoma: Treatment Practices and Outcomes Prior to Pediatric American Thyroid Association Guidelines Implementation. Pediatr Blood Cancer. 2025 Apr; 72(4):e31545.
    View in: PubMed
    Score: 0.035
  4. Implications of Implementing Children's Oncology Group Risk Stratification to Patients With Rhabdomyosarcoma Treated on European Paediatric Soft Tissue Sarcoma Study Group Clinical Trial. Pediatr Blood Cancer. 2025 Feb; 72(2):e31436.
    View in: PubMed
    Score: 0.035
  5. Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies. Pediatr Blood Cancer. 2024 Oct; 71(10):e31200.
    View in: PubMed
    Score: 0.034
  6. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Lancet Oncol. 2024 Jul; 25(7):912-921.
    View in: PubMed
    Score: 0.034
  7. Alpha-emitter therapy for pediatric relapsed metastatic pancreatic neuroendocrine tumor. Pediatr Blood Cancer. 2024 Jun; 71(6):e30961.
    View in: PubMed
    Score: 0.033
  8. Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children's Oncology Group studies. Pediatr Blood Cancer. 2023 Dec; 70(12):e30701.
    View in: PubMed
    Score: 0.032
  9. Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy. Cancer. 2022 12 01; 128(23):4150-4156.
    View in: PubMed
    Score: 0.030
  10. Soft Tissue and Visceral Organ Sarcomas With BCOR Alterations. J Pediatr Hematol Oncol. 2022 07 01; 44(5):195-200.
    View in: PubMed
    Score: 0.029
  11. Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report From the Children's Oncology Group ARST0332 Study. J Clin Oncol. 2021 12 10; 39(35):3927-3937.
    View in: PubMed
    Score: 0.028
  12. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Curr Probl Cancer. 2021 08; 45(4):100768.
    View in: PubMed
    Score: 0.027
  13. Neurocutaneous Melanocytosis and Leptomeningeal Melanoma. J Pediatr Hematol Oncol. 2021 03 01; 43(2):e195-e197.
    View in: PubMed
    Score: 0.027
  14. Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 04; 68(4):e28914.
    View in: PubMed
    Score: 0.027
  15. Treatment of central giant cell granuloma in children with denosumab. Pediatr Blood Cancer. 2021 03; 68(3):e28778.
    View in: PubMed
    Score: 0.026
  16. Systemic bevacizumab for recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol. 2020 Nov; 138:110352.
    View in: PubMed
    Score: 0.026
  17. Agenesis of the corpus callosum and hepatoblastoma. Am J Med Genet A. 2020 01; 182(1):224-228.
    View in: PubMed
    Score: 0.024
  18. Congenital spindle cell rhabdomyosarcoma. Pediatr Blood Cancer. 2019 11; 66(11):e27935.
    View in: PubMed
    Score: 0.024
  19. Malignant melanoma incidence among children and adolescents in Texas and SEER 13, 1995-2013. Pediatr Blood Cancer. 2019 06; 66(6):e27648.
    View in: PubMed
    Score: 0.023
  20. Pediatric Bronchial Carcinoid Tumors: A Case Series and Review of the Literature. J Pediatr Hematol Oncol. 2019 01; 41(1):67-70.
    View in: PubMed
    Score: 0.023
  21. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma. Thyroid. 2018 11; 28(11):1450-1454.
    View in: PubMed
    Score: 0.023
  22. Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinoma. Pediatr Blood Cancer. 2019 01; 66(1):e27469.
    View in: PubMed
    Score: 0.023
  23. Alveolar soft part sarcoma in children and young adults: A report of 69 cases. Pediatr Blood Cancer. 2018 05; 65(5):e26953.
    View in: PubMed
    Score: 0.022
  24. Borderline Ovarian Tumor in the Pediatric and Adolescent Population: A Case Series and Literature Review. J Pediatr Adolesc Gynecol. 2018 Feb; 31(1):48-54.
    View in: PubMed
    Score: 0.021
  25. Outcome of patients with intracranial relapse enrolled on national Wilms Tumor Study Group clinical trials. Pediatr Blood Cancer. 2017 Jul; 64(7).
    View in: PubMed
    Score: 0.020
  26. Juvenile Granulosa Cell Tumor of the Ovary: A Clinicopathologic Study. J Pediatr Adolesc Gynecol. 2017 Feb; 30(1):138-143.
    View in: PubMed
    Score: 0.020
  27. Gemcitabine-induced radiation recall myositis in a patient with relapsed nasopharyngeal carcinoma. Pract Radiat Oncol. 2017 Jan - Feb; 7(1):e19-e22.
    View in: PubMed
    Score: 0.019
  28. Multimodality Treatment of Pediatric Esthesioneuroblastoma. Pediatr Blood Cancer. 2016 Mar; 63(3):465-70.
    View in: PubMed
    Score: 0.018
  29. Risk-Based Therapy for Localized Osteosarcoma. Pediatr Blood Cancer. 2016 Mar; 63(3):412-7.
    View in: PubMed
    Score: 0.018
  30. Clinical outcomes of radiation therapy in the management of Langerhans cell histiocytosis. Am J Clin Oncol. 2014 Dec; 37(6):592-6.
    View in: PubMed
    Score: 0.017
  31. Effect of neoadjuvant chemotherapy on resectability of stage III and IV hepatoblastoma. Br J Surg. 2015 Jan; 102(1):108-13.
    View in: PubMed
    Score: 0.017
  32. Congenital abnormalities and hepatoblastoma: a report from the Children's Oncology Group (COG) and the Utah Population Database (UPDB). Am J Med Genet A. 2014 Sep; 164A(9):2250-5.
    View in: PubMed
    Score: 0.017
  33. Pulmonary function abnormalities in childhood cancer survivors treated with bleomycin. Pediatr Blood Cancer. 2014 Sep; 61(9):1679-84.
    View in: PubMed
    Score: 0.017
  34. High dose alkylator therapy for extracranial malignant rhabdoid tumors in children. Pediatr Blood Cancer. 2014 Aug; 61(8):1357-61.
    View in: PubMed
    Score: 0.017
  35. Correlation of pulmonary function abnormalities with dose volume histograms in children treated with lung irradiation. Pediatr Pulmonol. 2015 Jun; 50(6):596-603.
    View in: PubMed
    Score: 0.017
  36. Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved field radiation. Pediatr Blood Cancer. 2014 Jul; 61(7):1277-81.
    View in: PubMed
    Score: 0.016
  37. Nuclear protein in testis midline carcinoma misdiagnosed as adamantinoma. J Clin Oncol. 2014 May 20; 32(15):e57-60.
    View in: PubMed
    Score: 0.016
  38. Hepatoblastoma in a 15-month-old female with trisomy 13. Am J Med Genet A. 2014 Feb; 164A(2):472-5.
    View in: PubMed
    Score: 0.016
  39. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. Pediatr Blood Cancer. 2014 Apr; 61(4):756-9.
    View in: PubMed
    Score: 0.016
  40. Inflammatory myofibroblastic tumors in childhood. Pediatr Hematol Oncol. 2013 Oct; 30(7):640-5.
    View in: PubMed
    Score: 0.016
  41. A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors. PLoS One. 2013; 8(7):e68416.
    View in: PubMed
    Score: 0.016
  42. Correlation of clinical and dosimetric factors with adverse pulmonary outcomes in children after lung irradiation. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):942-8.
    View in: PubMed
    Score: 0.016
  43. Outcome of infants and young children with newly diagnosed ependymoma treated on the "Head Start" III prospective clinical trial. J Neurooncol. 2013 Jun; 113(2):285-91.
    View in: PubMed
    Score: 0.015
  44. A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors. Pediatr Blood Cancer. 2013 Jul; 60(7):1103-7.
    View in: PubMed
    Score: 0.015
  45. Pleuropulmonary blastoma: a single-institution experience. J Pediatr Hematol Oncol. 2012 Jul; 34(5):e182-5.
    View in: PubMed
    Score: 0.015
  46. An exploratory epidemiological study of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2012 Dec 15; 59(7):1324-6.
    View in: PubMed
    Score: 0.014
  47. Radiological features of Gorham's disease. Clin Radiol. 2012 Aug; 67(8):782-8.
    View in: PubMed
    Score: 0.014
  48. Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma. Pediatr Blood Cancer. 2012 Sep; 59(3):493-8.
    View in: PubMed
    Score: 0.014
  49. Supratentorial ependymoma in children: to observe or to treat following gross total resection? Pediatr Blood Cancer. 2012 Mar; 58(3):380-3.
    View in: PubMed
    Score: 0.013
  50. Gorham's disease and diffuse lymphangiomatosis in children and adolescents. Pediatr Blood Cancer. 2011 Apr; 56(4):667-70.
    View in: PubMed
    Score: 0.013
  51. Single site metastatic rhabdomyosarcoma: An INternational Soft Tissue saRcoma ConsorTium (INSTRuCT) pooled analysis. Eur J Cancer. 2025 Oct 16; 229:115793.
    View in: PubMed
    Score: 0.009
  52. The International Soft Tissue Sarcoma Consortium: The baseline analysis of rhabdomyosarcoma data. Cancer. 2025 Jul 15; 131(14):e35974.
    View in: PubMed
    Score: 0.009
  53. The impact of genetic ancestry on survival outcomes in pediatric rhabdomyosarcoma: A report from the Children's Oncology Group. HGG Adv. 2025 Jul 10; 6(3):100466.
    View in: PubMed
    Score: 0.009
  54. Radiation Therapy Dose Escalation Failed to Improve Local Control for Intermediate-Risk Rhabdomyosarcoma on ARST1431: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2025 Sep 01; 123(1):54-62.
    View in: PubMed
    Score: 0.009
  55. Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers. JCO Precis Oncol. 2025 Feb; 9:e2400556.
    View in: PubMed
    Score: 0.009
  56. Late Events Occurring After 5?Years in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2025 Jan; 72(1):e31421.
    View in: PubMed
    Score: 0.009
  57. Outcomes of relapsed favorable-histology Wilms tumor in non-clinical trial setting. Pediatr Blood Cancer. 2025 01; 72(1):e31347.
    View in: PubMed
    Score: 0.009
  58. Whole Lung Irradiation in Rhabdomyosarcoma With Lung Metastases: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2024 Dec 20; 42(36):4263-4270.
    View in: PubMed
    Score: 0.009
  59. Outcomes for patients with perineal and perianal rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Pediatr Blood Cancer. 2024 Nov; 71(11):e31303.
    View in: PubMed
    Score: 0.009
  60. The impact of margins and re-resection in pediatric synovial sarcoma. Cancer Med. 2024 Sep; 13(17):e70207.
    View in: PubMed
    Score: 0.009
  61. Event-free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2024 Jul; 71(7):e31009.
    View in: PubMed
    Score: 0.008
  62. Outcome of patients with relapsed or refractory nonrhabdomyosarcoma soft tissue sarcomas enrolled in phase 2 cooperative group clinical trials: A report from the Children's Oncology Group. Cancer. 2024 Jul 15; 130(14):2493-2502.
    View in: PubMed
    Score: 0.008
  63. Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group. JAMA Netw Open. 2024 03 04; 7(3):e244170.
    View in: PubMed
    Score: 0.008
  64. Survival of patients with orbital and eyelid rhabdomyosarcoma treated on Children's Oncology Group studies from 1997 to 2013: A report from the Children's Oncology Group. Cancer. 2023 06 01; 129(11):1735-1743.
    View in: PubMed
    Score: 0.008
  65. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Lancet Oncol. 2021 09; 22(9):1312-1321.
    View in: PubMed
    Score: 0.007
  66. Metabolic response as assessed by 18 F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer Med. 2021 02; 10(3):857-866.
    View in: PubMed
    Score: 0.007
  67. Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups. Pediatr Blood Cancer. 2021 03; 68(3):e28832.
    View in: PubMed
    Score: 0.007
  68. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer. 2021 03 15; 127(6):946-956.
    View in: PubMed
    Score: 0.007
  69. Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2021 01 15; 127(2):275-283.
    View in: PubMed
    Score: 0.007
  70. Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma. Pediatr Blood Cancer. 2021 01; 68(1):e28741.
    View in: PubMed
    Score: 0.006
  71. Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer. 2020 10; 67(10):e28417.
    View in: PubMed
    Score: 0.006
  72. Mentors' perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2019 10; 66(10):e27920.
    View in: PubMed
    Score: 0.006
  73. Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association With Outcomes: Single-center Experience. J Pediatr Gastroenterol Nutr. 2019 05; 68(5):695-699.
    View in: PubMed
    Score: 0.006
  74. Multimodal molecular analysis of an atypical small cell carcinoma of the ovary, hypercalcemic type. Cold Spring Harb Mol Case Stud. 2018 10; 4(5).
    View in: PubMed
    Score: 0.006
  75. Cholangiocarcinoma Among Children and Adolescents: A Review of the Literature and Surveillance, Epidemiology, and End Results Program Database Analysis. J Pediatr Gastroenterol Nutr. 2018 01; 66(1):e12-e18.
    View in: PubMed
    Score: 0.005
  76. Local therapy to distant metastatic sites in stage IV rhabdomyosarcoma. Pediatr Blood Cancer. 2018 Feb; 65(2).
    View in: PubMed
    Score: 0.005
  77. Hepatocellular malignant neoplasm, NOS: a clinicopathological study of 11 cases from a single institution. Histopathology. 2017 Nov; 71(5):813-822.
    View in: PubMed
    Score: 0.005
  78. Radiotherapy after high-dose chemotherapy with autologous hematopoietic cell rescue: Quality assessment of Head Start III. Pediatr Blood Cancer. 2017 Oct; 64(10).
    View in: PubMed
    Score: 0.005
  79. Myofibroma in Infancy and Childhood. J Pediatr Hematol Oncol. 2017 04; 39(3):e136-e139.
    View in: PubMed
    Score: 0.005
  80. Neuroendocrine Tumor of the Appendix in Children. J Pediatr Hematol Oncol. 2017 03; 39(2):97-102.
    View in: PubMed
    Score: 0.005
  81. Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.005
  82. The diagnostic and prognostic value of SALL4 in hepatoblastoma. Histopathology. 2016 Nov; 69(5):822-830.
    View in: PubMed
    Score: 0.005
  83. Translocation t(7;12) as the sole chromosomal abnormality resulting in ACTB-GLI1 fusion in pediatric gastric pericytoma. Hum Pathol. 2016 07; 53:137-41.
    View in: PubMed
    Score: 0.005
  84. Pilot Feasibility Study of Comprehensive Pulmonary Evaluation Following Lung Radiation Therapy. J Pediatr Hematol Oncol. 2015 Oct; 37(7):e412-8.
    View in: PubMed
    Score: 0.005
  85. Zoledronic Acid for the Treatment of Children With Refractory Central Giant Cell Granuloma. J Pediatr Hematol Oncol. 2015 Aug; 37(6):e399-401.
    View in: PubMed
    Score: 0.005
  86. Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma. Pediatr Hematol Oncol. 2015 Feb; 32(1):26-31.
    View in: PubMed
    Score: 0.004
  87. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors. Clin Cancer Res. 2014 Dec 15; 20(24):6314-23.
    View in: PubMed
    Score: 0.004
  88. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov. 2014 Aug; 4(8):928-41.
    View in: PubMed
    Score: 0.004
  89. Carnitine and cardiac dysfunction in childhood cancer survivors treated with anthracyclines. Cancer Epidemiol Biomarkers Prev. 2014 Jun; 23(6):1109-14.
    View in: PubMed
    Score: 0.004
  90. Teratoid hepatoblastoma with abundant cholangioblastic component in a child with full trisomy 13. Pediatr Dev Pathol. 2013 Nov-Dec; 16(6):438-41.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.